Active, not recruitingPHASE1, PHASE2NCT03600883
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MDAmgen
- Intervention
- sotorasib(drug)
- Enrollment
- 713 target
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2018 – 2026
Study locations (30)
- City of Hope National Medical Center, Duarte, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- University of California at SF, San Francisco, California, United States
- Sarcoma Oncology Research Center LLC, Santa Monica, California, United States
- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark, Delaware, United States
- University of Florida Health, Gainesville, Florida, United States
- AdventHealth Orlando Infusion Center, Orlando, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute, Atlanta, Georgia, United States
- Indiana University, Indianapolis, Indiana, United States
- American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03600883 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →